WO1996000068A3 - Therapie combinee contre les infections a vih - Google Patents
Therapie combinee contre les infections a vih Download PDFInfo
- Publication number
- WO1996000068A3 WO1996000068A3 PCT/US1995/007690 US9507690W WO9600068A3 WO 1996000068 A3 WO1996000068 A3 WO 1996000068A3 US 9507690 W US9507690 W US 9507690W WO 9600068 A3 WO9600068 A3 WO 9600068A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hiv
- combination therapy
- hiv infection
- combination
- infection
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- 208000030507 AIDS Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108010010369 HIV Protease Proteins 0.000 abstract 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 abstract 1
- 229940122440 HIV protease inhibitor Drugs 0.000 abstract 1
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 239000004030 hiv protease inhibitor Substances 0.000 abstract 1
- 239000002955 immunomodulating agent Substances 0.000 abstract 1
- 229940121354 immunomodulator Drugs 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical class CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 abstract 1
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 abstract 1
- 229960000689 nevirapine Drugs 0.000 abstract 1
- 229940042443 other antivirals in atc Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95923935A EP0767664A2 (fr) | 1994-06-27 | 1995-06-23 | Therapie combinee contre les infections a vih |
MX9700036A MX9700036A (es) | 1994-06-27 | 1995-06-23 | Combinacion de compuestos, uso en la preparacion de composiciones para tratar infeccion por el vir s de inmunodeficiencia humana, y composiciones obtenidas. |
AU28638/95A AU2863895A (en) | 1994-06-27 | 1995-06-23 | Combination therapy for hiv infection |
CZ963751A CZ375196A3 (en) | 1994-06-27 | 1995-06-23 | Combination of active compounds against hiv and pharmaceutical composition containing thereof |
SK1639-96A SK163996A3 (en) | 1994-06-27 | 1995-06-23 | Combinated medicament and pharmaceutical composition containing its, used to therapy of hiv infection |
KR1019960707469A KR970703770A (ko) | 1994-06-27 | 1995-06-23 | 사람 면역결핍 바이러스 감염에 대한 배합 치료(Combination therapy for HIV infection) |
JP8503245A JPH10503178A (ja) | 1994-06-27 | 1995-06-23 | Hiv感染のための組合わせ療法 |
FI965196A FI965196A (fi) | 1994-06-27 | 1996-12-23 | HIV-infektion yhdistelmähoito |
NO965591A NO965591D0 (no) | 1994-06-27 | 1996-12-27 | Kombinasjonsbehandling av HIV-infeksjon |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26708594A | 1994-06-27 | 1994-06-27 | |
US267,085 | 1994-06-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996000068A2 WO1996000068A2 (fr) | 1996-01-04 |
WO1996000068A3 true WO1996000068A3 (fr) | 1996-02-22 |
Family
ID=23017251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1995/007690 WO1996000068A2 (fr) | 1994-06-27 | 1995-06-23 | Therapie combinee contre les infections a vih |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0767664A2 (fr) |
JP (1) | JPH10503178A (fr) |
AU (1) | AU2863895A (fr) |
CA (1) | CA2193221A1 (fr) |
CZ (1) | CZ375196A3 (fr) |
FI (1) | FI965196A (fr) |
HU (1) | HUT76546A (fr) |
IL (1) | IL114208A0 (fr) |
MX (1) | MX9700036A (fr) |
NO (1) | NO965591D0 (fr) |
PL (1) | PL317876A1 (fr) |
SK (1) | SK163996A3 (fr) |
WO (1) | WO1996000068A2 (fr) |
ZA (1) | ZA955269B (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6689761B1 (en) | 1995-02-01 | 2004-02-10 | Merck & Co., Inc. | Combination therapy for HIV infection |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
EP0872233A1 (fr) * | 1997-04-14 | 1998-10-21 | Janssen Pharmaceutica N.V. | Médicaments antirétroviraux à biodisponibilité améliorée |
GB2324242A (en) * | 1997-04-18 | 1998-10-21 | Atindra Nath Chakrabarty | Medicaments for treating viral infections |
AU775360B2 (en) | 1999-09-24 | 2004-07-29 | Janssen Pharmaceutica N.V. | Antiviral compositions |
EP4215900A1 (fr) | 2015-09-23 | 2023-07-26 | Malvern Panalytical Limited | Caractérisation de particules |
-
1995
- 1995-06-19 IL IL11420895A patent/IL114208A0/xx unknown
- 1995-06-23 JP JP8503245A patent/JPH10503178A/ja active Pending
- 1995-06-23 CA CA002193221A patent/CA2193221A1/fr not_active Abandoned
- 1995-06-23 CZ CZ963751A patent/CZ375196A3/cs unknown
- 1995-06-23 EP EP95923935A patent/EP0767664A2/fr not_active Withdrawn
- 1995-06-23 WO PCT/US1995/007690 patent/WO1996000068A2/fr not_active Application Discontinuation
- 1995-06-23 HU HU9603567A patent/HUT76546A/hu unknown
- 1995-06-23 AU AU28638/95A patent/AU2863895A/en not_active Withdrawn
- 1995-06-23 MX MX9700036A patent/MX9700036A/es unknown
- 1995-06-23 PL PL95317876A patent/PL317876A1/xx unknown
- 1995-06-23 SK SK1639-96A patent/SK163996A3/sk unknown
- 1995-06-26 ZA ZA955269A patent/ZA955269B/xx unknown
-
1996
- 1996-12-23 FI FI965196A patent/FI965196A/fi not_active Application Discontinuation
- 1996-12-27 NO NO965591A patent/NO965591D0/no unknown
Non-Patent Citations (4)
Title |
---|
JAMES E. F. REYNOLDS: "Martindale; The Extra Pharmacopoeia, Thirtieth edition", THE PHARMACEUTICAL PRESS, LONDON * |
KARL D. HARGRAVE, JOHN R. PROUDFOOT ET AL: "NOVEL NON-NUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE. 1. TRICYCLIC PYRIDOBENZO- AND DIPYRIDODIAZEPINONES", J. MED. CHEM., vol. 34, USA, pages 2231 - 2241 * |
RUDI PAUWELS, KOEN ANDRIES ET AL: "POTENT AND HIGHLY SELECTIVE HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INHIBITION BY A SERIES OF ALFA-ANILINOPHENYLACETAMIDE DERIVATIVES TARGETED AT HIV-1 REVERSE TRANSCRIPTASE", PROC. NATL. SCI., vol. 90, no. 5, 1 March 1993 (1993-03-01), USA, pages P1711 - P1715 * |
VACCA, DORSEY ET AL: "L-735,524: An orally bioavailable human immunodeficieny virus type 1 protease inhibitor", PROC. NATL. ACAD. SCI., vol. 91, no. 9, USA, pages 4096 - 4100 * |
Also Published As
Publication number | Publication date |
---|---|
FI965196A0 (fi) | 1996-12-23 |
CZ375196A3 (en) | 1997-07-16 |
HUT76546A (en) | 1997-09-29 |
FI965196A (fi) | 1996-12-23 |
PL317876A1 (en) | 1997-04-28 |
HU9603567D0 (en) | 1997-02-28 |
CA2193221A1 (fr) | 1996-01-04 |
JPH10503178A (ja) | 1998-03-24 |
AU2863895A (en) | 1996-01-19 |
SK163996A3 (en) | 1997-08-06 |
IL114208A0 (en) | 1995-10-31 |
NO965591L (no) | 1996-12-27 |
EP0767664A2 (fr) | 1997-04-16 |
ZA955269B (en) | 1996-02-02 |
NO965591D0 (no) | 1996-12-27 |
MX9700036A (es) | 1997-04-30 |
WO1996000068A2 (fr) | 1996-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2725392A (en) | Hiv protease inhibitors | |
ATE377011T1 (de) | Gamma-hydroxy-2-(fluoralkylaminocarbonyl)-1- piperazinpentanamide als hiv-proteasehemmer | |
MY109834A (en) | Benzoxazinones as inhibitors of hiv reverse transcriptase | |
EP0766674A4 (fr) | Nouveaux inhibiteurs de protease de vih | |
NO953876D0 (no) | HIV-proteaseinhibitorer som er anvendbare for behandling av AIDS | |
BR9408305A (pt) | Composto composição farmacêutica processos para tratamento de aids e da infecção por hiv para preparação da infecção por hiv e para inibição de protease de hiv e combinação de compostos | |
MX9705916A (es) | Terapia de combinacion para infeccion por vih usando el inhibidor de proteasa de vih indinavir y el inhibidor de transcriptasa inversa 3tc, opcionalmente junto con azt, ddi, o ddc. | |
WO1996000068A3 (fr) | Therapie combinee contre les infections a vih | |
EP0774969B8 (fr) | Combinaison de l'inhibiteur de la protease du vih | |
WO2002096359A3 (fr) | Inhibiteurs de la protease du vih pentanamide piperazine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 95194689.7 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA UZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KR KZ LK LR LT LV MD MG MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA UZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 288948 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995923935 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2193221 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 163996 Country of ref document: SK Ref document number: PV1996-3751 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 965196 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/000036 Country of ref document: MX |
|
WWP | Wipo information: published in national office |
Ref document number: 1995923935 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: PV1996-3751 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: PV1996-3751 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995923935 Country of ref document: EP |